IVVD 8-K: Invivyd launches collaboration to assess post-vaccination syndrome therapy

Rhea-AI Filing Summary

Invivyd, Inc. (Nasdaq: IVVD) filed an 8-K to disclose that, on July 2, 2025, it issued a press release announcing the formation of the SPEAR (Spike Protein Elimination and Recovery) Study Group. The collaboration brings Invivyd together with leading researchers to evaluate the effects of the company’s monoclonal antibody therapy on two patient populations: 1) individuals suffering from Long COVID and 2) those experiencing COVID-19 post-vaccination syndrome.

The filing contains no financial results, trial data, or guidance. Instead, it simply furnishes the press release as Exhibit 99.1 under Item 8.01 (Other Events) and lists customary exhibit and signature information.

Positive

• Strategic research collaboration: Formation of the SPEAR Study Group signals continued pursuit of new indications for Invivyd’s monoclonal antibody platform.

Negative

• Lack of quantitative information: The 8-K provides no clinical data, financial commitments, or timelines, offering little guidance on potential impact or costs.

Insights

Biotechnology Analyst

TL;DR: 8-K notes new research collaboration; no financial metrics, modest strategic signal, limited immediate valuation impact.

Analysis: The disclosure is informational: Invivyd is partnering with external experts via the SPEAR Study Group to study its monoclonal antibody’s potential benefits in Long COVID and post-vaccination complications. Such collaborations can improve clinical credibility and broaden potential indications, but today’s filing offers no efficacy data, development timelines, funding details, or commercial projections. Consequently, investors receive limited actionable insight beyond confirmation that the company is pursuing additional exploratory work. Share-price impact is therefore expected to be modest and contingent on future study outcomes.

false000183203800018320382025-07-022025-07-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 2, 2025

Invivyd, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-40703		85-1403134
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1601 Trapelo Road, Suite 178 Waltham, MA		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (781) 819-0080

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		IVVD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On July 2, 2025, Invivyd, Inc. issued a press release entitled “Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.” A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated July 2, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		INVIVYD, INC.
Date: July 2, 2025		By:	/s/ Jill Andersen
			Jill Andersen
			Chief Legal Officer and Corporate Secretary

FAQ

What did Invivyd (IVVD) announce on July 2, 2025?

Invivyd announced the creation of the SPEAR Study Group to study its monoclonal antibody therapy for Long COVID and post-vaccination syndrome.

Does the 8-K include any financial results for Invivyd?

No. The filing contains no revenue, expense, or earnings data; it only furnishes the press release as an exhibit.

What is the purpose of the SPEAR Study Group?

The group will assess the effects of Invivyd’s monoclonal antibody therapy on Long COVID and COVID-19 post-vaccination syndrome patients.

Were any clinical trial outcomes disclosed?

No. The 8-K does not provide trial results or efficacy data.

Is there any guidance on regulatory timelines?

The filing does not mention regulatory milestones or anticipated timelines for the study.